wire - news in brief
« BACK
Pharmacology - Innovation - 18.11.2021
Pharmacology - Social Sciences - 11.10.2021
Health - Pharmacology - 20.07.2021 
Impaired humoral and cellular immune responses to SARSCov-2 mRNA vaccine in virus unexposed patients receiving maintenance hemodialysis
The ROMANOV study found impaired humoral and cellular immune responses to SARSCov-2 mRNA vaccine in virus unexposed patients receiving maintenance hemodialysis The ROMANOV study found impaired humoral
Pharmacology - 22.03.2021 
Massive clonal expansion of polycytotoxic skin and blood CD8+ T cells in patients with toxic epidermal necrolysis patients
Publication of CIRI in Sciences advances on March 19, 2021. Toxic epidermal necrolysis (TEN) is a life-threatening cutaneous adverse drug reaction.
Pharmacology - 29.06.2020
Health - Pharmacology - 06.05.2020
Health - Pharmacology - 15.04.2020
Health - Pharmacology - 27.05.2019
Pharmacology - Life Sciences - 11.05.2018
Pharmacology
Results 1 - 9 of 9.
The ROMANOV study found impaired humoral and cellular immune responses to SARSCov-2 mRNA vaccine in virus unexposed patients receiving maintenance hemodialysis The ROMANOV study found impaired humoral
Publication of CIRI in Sciences advances on March 19, 2021. Toxic epidermal necrolysis (TEN) is a life-threatening cutaneous adverse drug reaction.
Covid-19: CIRI mobilizes its teams to understand the immune response against Coronavirus in patients
A CIRI project, in collaboration with HCL, has united CIRI immunologists to work on understanding the immune response to Coronavirus in patients.
A CIRI project, in collaboration with HCL, has united CIRI immunologists to work on understanding the immune response to Coronavirus in patients.
Inhibitory checkpoint receptors control CD8+ resident memory T cells to prevent skin allergy
Publication by the International Center for Infectiology Research (CIRI) in The Journal of Allergy and Clinical Immunology on January 14, 2019.
Publication by the International Center for Infectiology Research (CIRI) in The Journal of Allergy and Clinical Immunology on January 14, 2019.
Farnesoid X receptor-- is a proviral host factor for hepatitis B virus that is inhibited by ligands in vitro and in vivo
Farnesoid X receptor- is a proviral host factor for hepatitis B virus that is inhibited by ligands in vitro and in vivo Abstract: Hepatitis B virus (HBV) infection and bile acid (BA) metabolism are in
Farnesoid X receptor- is a proviral host factor for hepatitis B virus that is inhibited by ligands in vitro and in vivo Abstract: Hepatitis B virus (HBV) infection and bile acid (BA) metabolism are in
